38 results
Thumbnail

D1.342 - Therapeutic Potential of LCAA-PSF in Atopic Dermatitis: Insights from an MC903-Induced Mouse Model

Thumbnail

D1.349 - Age-related fungal molecular clusters revealed by allergen chip assay in Eastern France

Thumbnail

D1.352 - Assessment of the Efficacy of Mepolizumab in Modulating Disease Activity in Eosinophilic Granulomatosis with Polyangiitis: A 12-Month Analysis Evaluating the Birmingham Vasculitis Activity Score

Thumbnail

D1.343 - Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis

Thumbnail

D1.344 - Role of nodular lymphoid hyperplasia as immunologic precursor of IBD development in patients with IBS-like symptoms: an observational, ambispectic, muliticenter study “The NILO study”

Thumbnail

D1.345 - Biologic Agents in Neurosarcoidosis: Efficacy and Future Perspectives from a Single-Center Cohort Study

Thumbnail

D1.346 - Immunology and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers in stratifying disease risk and severity for precision medicine

Thumbnail

D1.347 - Biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms

Thumbnail

D1.350 - A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes

Thumbnail

D1.351 - The impact of Lactobacillus on the expression of NLRP3, IL-1β and HMGB1 in women with endometriosis associated infertility

Thumbnail

D1.353 - When eosinophils surpass the limits without a known cause

Thumbnail

D1.355 - Impact of mesothelin in women with endometriosis

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years